What’s New: In this first take following tonight’s results, we touch on: 1. No quarterly subscriber/ARM figures starting 1Q25; new annual revenue guidance instead 2. Revenue growth shifting from subscribers to ARM through 2024 3. Little new advertising color, we expect updated metrics at Upfront, and 4. New capital structure targets driving more flexibility.
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart d...
Ahead of Thursday PM’s earnings report, we review what to look and listen for in the shareholder letter and earnings broadcast, our top questions for management, and potential positive and negative catalysts for NFLX. We also update our thoughts on key controversies and investment drivers,
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.